Neutrophil-targeted liposomal platform: A shift in novel approach for early detection and treatment of cancer metastasis
Tumor metastasis is responsible for 90 % of cancer-associated deaths, and its early detection may decrease the likelihood of mortality. Studies have demonstrated that metastasis results from the interaction between "seeds" (tumor cells) and "soil" (pre-metastatic niche, PMN). As the first and most abundant immune cells to be recruited to PMN, neutrophils play a key role in the ultimate formation of metastatic foci through mechanisms such as supporting tumor cell growth, promoting angiogenesis, and shaping an immune-suppressive microenvironment. In this study, two distinct types of sialic acid (SA)-modified liposomes were prepared to target and regulate pro-metastatic neutrophils through the <i>l</i>-selectin receptor. One of these liposomes, named ICG@SAL, was used to encapsulate indocyanine green (ICG) and was specifically designed for the early detection of cancer metastasis. The other liposome, referred to as ABE/Cur@SAL, co-loaded abemaciclib (ABE) and curcumin (Cur), with the intention of suppressing the progression of metastatic tumor. Fluorescence imaging results from the mouse spontaneous metastasis model indicated that ICG@SAL demonstrated faster targeting and stronger accumulation in the metastatic organs than unmodified ICG liposomes (ICG@CL). This suggested that ICG@SAL could detect tumor metastasis at an early stage. The therapy with co-loaded liposomes in the mouse experimental lung metastasis model indicated that ABE/Cur@SAL could inhibit regulatory T (Treg) cell proliferation, enhance effector T cell activity and reduce tumorigenic factor release, implying that ABE/Cur@SAL could inhibit tumor metastasis. Overall, our work provided a sensitive and convenient approach to early diagnosis and treatment of tumor metastasis. ICG@SAL could be employed for the early detection of tumor metastasis, while ABE/Cur@SAL could be used to inhibit the development of tumor metastasis when early metastasis was identified.
Authors
- Lijiang Chen (ORCID: https://orcid.org/0000-0001-6168-5419)
- Zehua Cheng
- Lianrui Cao
- Chao Shen (ORCID: https://orcid.org/0000-0003-0386-6689)
- Zehao Li (ORCID: https://orcid.org/0000-0002-3867-1462)
- Cong Li (ORCID: https://orcid.org/0000-0003-0020-4663)
- Zeyu Wang (ORCID: https://orcid.org/0000-0002-6675-5399)
- Kexin Zhang (ORCID: https://orcid.org/0000-0002-3764-266X)
- Zhihang Li (ORCID: https://orcid.org/0000-0003-3621-7036)
- Lihong Wang (ORCID: https://orcid.org/0009-0001-5257-3578)
Institutions
- Liaoning University (CN)
Publication Details
- Journal
- Asian Journal of Pharmaceutical Sciences
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.ajps.2024.100949
- Citations
- 2
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- Department of Education of Liaoning Province
- Liaoning University
- Doctoral Start-up Foundation of Liaoning Province
- Department of Science and Technology of Liaoning Province